BioSyent (RX) Reports $6.0M Q3 Operating Cash Flow
BioSyent reported combined operating cash flows of $6.0M in Q3 2026, deployed $1.7M on share buybacks and $0.6M on dividends, and repaid its remaining $2.0M acquisition debt. No prior-period comparisons were provided in the release.Material DetailsContext by AI AnalystThis is a quarterly financial…